Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | RGS4 | P49798 | 2/20 | 0.41 |
| ▸ | RGS8 | P57771 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | LITAF | Q99732 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9849016 | 0.91 | ALDH1A1 (0.74) | ALDH1A1RGS4RGS8KDM4EMAPT | |
| SCHEMBL2329963 | 0.85 | ALDH1A1 (0.47) | ALDH1A1KDM4EMAPTGAAGFER | |
| SCHEMBL1545990 | 0.81 | ALDH1A1 (0.75) | ALDH1A1KDM4EMAPTMEN1THRB | |
| SCHEMBL239409 | 0.79 | ALDH1A1 (0.45) | ALDH1A1KDM4EMAPTGAAGFER | |
| SCHEMBL5551663 | 0.77 | ALDH1A1 (0.47) | ALDH1A1KDM4EMAPTGAAGFER | |
| SCHEMBL10957985 | 0.77 | ALDH1A1 (1.00) | ALDH1A1GAACYP3A4HPGDTSHR | |
| SCHEMBL1948066 | 0.76 | ADORA2B (0.46) | ALDH1A1RGS4RGS8KDM4EMAPT | |
| SCHEMBL20392162 | 0.75 | RGS4 (0.53) | ALDH1A1RGS4RGS8ADORA2AADORA2B | |
| SCHEMBL1943523 | 0.75 | ALDH1A1 (0.39) | ALDH1A1KDM4EMAPTGAAGFER | |
| SCHEMBL28968573 | 0.75 | CYP3A4 (0.48) | ALDH1A1KDM4EMAPTGAAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8609671-B2 | Method of inhibiting hepatic fibrosis as a result of liver replacement or repair using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8466129-B2 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120220608-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. | 2012-08-30 | — | — | US | disclosed |
| EP-1789053-B1 | METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES INC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8188099-B2 | Method of decreasing hepatotoxic side effects using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110184002-A1 | METHOD OF TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| EP-2311462-A1 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7795268-B2 | administration of therapeutically effective amount of 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione, wherein hepatic disease is selected from necrosis, fibrosis, cholestasis, cirrhosis, viral and alcoholic hepatitis, ingestion of hepatotoxic drugs | GILEAD PALO ALTO, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100105706-A1 | METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD PALO ALTO, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20090137802-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. | 2009-05-28 | — | — | US | disclosed |
| US-7521554-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070219221-A1 | administration of therapeutically effective amount of 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione, wherein hepatic disease is selected from necrosis, fibrosis, cholestasis, cirrhosis, viral and alcoholic hepatitis, ingestion of hepatotoxic drugs | GILEAD SCIENCES, INC. | 2007-09-20 | — | — | US | disclosed |
| US-20060281921-A1 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2006-12-14 | — | — | US | disclosed |
| US-7125993-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20060159627-A1 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2006-07-20 | — | — | US | disclosed |
| US-20060058322-A1 | Method of wound healing using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2006-03-16 | — | — | US | disclosed |
| US-20040176399-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 156/4885RGS4 2213/4885RGS8 1989/4885 |
| US-20090137802-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 870/4885RGS4 1011/4885RGS8 514/4885 |
| US-20070219221-A1 | administration of therapeutically effective amount of 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione, wherein hepatic disease is selected from necrosis, fibrosis, cholestasis, cirrhosis, viral and alcoholic hepatitis, ingestion of hepatotoxic drugs | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 150/4885RGS4 4371/4885RGS8 1514/4885 |
| US-20060281921-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 870/4885RGS4 1011/4885RGS8 514/4885 |
| US-20120220608-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 156/4885RGS4 2213/4885RGS8 1989/4885 |
| US-20100105706-A1 | METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 1233/4885RGS4 1167/4885RGS8 878/4885 |
| US-20040176399-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 779/4885RGS4 907/4885RGS8 762/4885 |
| US-20110184002-A1 | METHOD OF TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 190/4885RGS4 2061/4885RGS8 1939/4885 |
| US-20060058322-A1 | Method of wound healing using A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 470/4885RGS4 677/4885RGS8 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.